Clinical Trial Update: Ursofalk Tablets (500 mg) Versus Ursofalk Capsules (250 mg) in the Treatment of Primary Biliary Cirrhosis [Phase 4]

View source ↗

Summary

Phase 4 trial comparing Ursofalk tablets (500 mg) vs Ursofalk capsules (250 mg) for primary biliary cirrhosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Cirrhosis

Drugs mentioned

• Ursofalk (Ursodeoxycholic acid)

Snippet

Sponsor: Dr. Falk Pharma GmbH | Conditions: Primary Biliary Cirrhosis | Phase 4 | Status: COMPLETED